Sugi Predict

Sugi Predict / Compounds / SCHEMBL9941526

SCHEMBL9941526

SCHEMBL9941526

N#Cc1cccc(Cn2ncc3c(N)cccc32)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN1 Q05586 5/20 0.48
▸ GRIN2B Q13224 5/20 0.48
▸ CYP19A1 P11511 1/20 0.47
▸ CYP11B1 P15538 1/20 0.47
▸ CYP11B2 P19099 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ ERBB2 P04626 1/20 0.42
▸ BUB1 O43683 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ CREBBP Q92793 1/20 0.40
▸ QPCT Q16769 2/20 0.39
▸ MPO P05164 1/20 0.39
▸ QPCTL Q9NXS2 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1172524 0.81 RECQL (0.58) ALDH1A1ADORA2AADORA1MPOBRD4
SCHEMBL25301075 0.77 KMT2A (0.54) ALDH1A1EGFRADORA2AADORA1
SCHEMBL9941849 0.77 GRIN1 (0.50) GRIN1GRIN2BALDH1A1
SCHEMBL9941863 0.76 ALDH1A1 (0.56) GRIN1GRIN2BCYP11B1ALDH1A1ADORA2A
SCHEMBL5592559 0.75 KDM4E (0.49) GRIN1GRIN2BCYP11B1ALDH1A1MPO
SCHEMBL20118749 0.75 HSP90AA1 (0.57) ALDH1A1ADORA3ADORA2AADORA2BADORA1
SCHEMBL30860855 0.75 MKNK1 (0.41) ALDH1A1MPOBRD4
SCHEMBL27227945 0.75 MKNK1 (0.41) ALDH1A1MPOBRD4
SCHEMBL9941816 0.74 MAOB (0.48) ALDH1A1MPORECQL
SCHEMBL17044159 0.73 GRIN1 (0.47) GRIN1GRIN2BCYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-06-02 — — US disclosed
US-20180086758-A1 SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2018-03-29 — — US disclosed
US-9809590-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-11-07 — — US disclosed
CN-103347882-B Substituted N- (1H-indazol-4-yl) imidazo [1,2-a ] pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-05-11 — — CN disclosed
US-20160002232-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-01-07 — — US disclosed
US-9174981-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-11-03 — — US disclosed
EP-2651939-B1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-04-08 — — EP disclosed
EP-2651939-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2013-10-23 — — EP disclosed
US-20130274244-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. 2013-10-17 — — US disclosed
CN-103347882-A Substituted N- (1H-indazol-4-yl) imidazo [1,2-a ] pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC 2013-10-09 — — CN disclosed
WO-2012082689-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274244-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS MUSK, FGFR1, FRK GRIN1 1422/4885GRIN2B 2266/4885CYP19A1 3072/4885
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors MUSK, FGFR1, PDGFRA GRIN1 1572/4885GRIN2B 2337/4885CYP19A1 2894/4885
US-20180086758-A1 SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS LTK, MUSK, FGFR1 GRIN1 1782/4885GRIN2B 2413/4885CYP19A1 2843/4885
US-20160002232-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS MUSK, TYRO3, IRAK3 GRIN1 1347/4885GRIN2B 1934/4885CYP19A1 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.